Loading...

MedXY AI/MedXY News/Tag: obesity

MedXY News

EnglishTag

obesity

108 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.

Section: newsNov 23, 2025

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

An exploratory analysis of the PATS randomized trial found early adenotonsillectomy reduced 12‑month systolic and diastolic BP percentiles versus watchful waiting in children with mild obstructive sleep‑disordered breathing, with larger DBP

Section: CardiologyNov 21, 2025

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi

Section: Diabetes & EndocrinologyNov 14, 2025

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

Section: CardiologyNov 11, 2025

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2

Section: Critical CareNov 7, 2025

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits

A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c

Section: GastroenterologyNov 7, 2025

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

In a large prospective cohort, obese BMI (≥30) was associated with worse post-concussion neurocognitive outcomes and a persistently proinflammatory blood biomarker profile, despite fewer baseline symptoms. Findings suggest obesity modifies

Section: Diabetes & EndocrinologyNov 5, 2025

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Section: Diabetes & EndocrinologyNov 1, 2025

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

New evidence from the UK Biobank reveals that clinical obesity, defined by obesity-related dysfunctions, significantly elevates all-cause mortality risk. Early detection and intervention are key to reducing mortality associated with both pr

Section: Diabetes & EndocrinologyOct 29, 2025

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt

Section: Diabetes & EndocrinologyOct 29, 2025

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patie

Section: GastroenterologyOct 27, 2025

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

A large retrospective cohort study reveals bariatric surgery markedly lowers the incidence of key metabolic comorbidities compared to weight management alone in obese veterans, supporting its role in durable obesity-related risk reduction.

Section: Diabetes & EndocrinologyOct 27, 2025

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.

Section: Internal MedicineOct 27, 2025

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat

Section: Diabetes & EndocrinologyOct 26, 2025

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions

Integrating Obesity Management into Cardiac Rehabilitation: Challenges, Evidence, and Future Directions

Obesity management in cardiac rehabilitation (CR) is underutilized despite its cardiovascular benefits. This review explores the evidence, complexities, patient perspectives, and healthcare provider attitudes, emphasizing tailored strategie

Section: CardiologyOct 24, 2025

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Section: Diabetes & EndocrinologyOct 22, 2025

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation i

Section: Diabetes & EndocrinologyOct 20, 2025

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Section: Diabetes & EndocrinologyOct 19, 2025

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Section: Diabetes & EndocrinologyOct 19, 2025

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits

Section: Diabetes & EndocrinologyOct 13, 2025

Prev 1 2 3 4 5 6 Next